title: Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit.
authors.forename: Borje S
authors.initials: BS
authors.lastname: Andersson
authors.forename: Ashwin
authors.initials: A
authors.lastname: Kashyap
authors.forename: Daniel
authors.initials: D
authors.lastname: Couriel
authors.forename: Thomas
authors.initials: T
authors.lastname: Madden
authors.forename: Marcos
authors.initials: M
authors.lastname: de Lima
authors.forename: Peter F
authors.initials: PF
authors.lastname: Thall
authors.forename: Hugo
authors.initials: H
authors.lastname: Fernandez
authors.forename: William P
authors.initials: WP
authors.lastname: Vaughan
authors.forename: Roy
authors.initials: R
authors.lastname: Jones
authors.forename: John R
authors.initials: JR
authors.lastname: Wingard
authors.forename: Karl G
authors.initials: KG
authors.lastname: Blume
authors.forename: Richard E
authors.initials: RE
authors.lastname: Champlin
mesh_terms: D000284:Administration, Oral; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D001682:Biological Availability; D002066:Busulfan / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D019337:Hematologic Neoplasms / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007275:Injections, Intravenous; D015203:Reproducibility of Results
chemical_list: D018906:Antineoplastic Agents, Alkylating; D002066:Busulfan